Evidence map›Paper›PMID 37316916›Full record

ArticleBiomarker research2023

A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma.

Aditi Patel, Parina Patel, Dushyant Mandlik, Kaustubh Patel, Pooja Malaviya, Kaid Johar, Krishna B S Swamy, Shanaya Patel, Vivek Tanavde

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Biomarker research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Salivary Extracellular Vesicles: Biomarkers and Beyond in Human Diseases.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Sample-to-answer salivary miRNA testing: New frontiers in point-of-care diagnostic technologies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Aditi Patel *Biological and Life Sciences, School of Arts and Sciences, Ahmedabad University, Ahmedabad, 380009, Gujarat, India.
Parina Patel *Biological and Life Sciences, School of Arts and Sciences, Ahmedabad University, Ahmedabad, 380009, Gujarat, India.
Dushyant MandlikDepartment of Head and Neck Oncology, HCG Cancer Centre, Ahmedabad, Gujarat, India.
Kaustubh PatelDepartment of Head and Neck Oncology, HCG Cancer Centre, Ahmedabad, Gujarat, India.
Pooja MalaviyaDepartment of Cell and Molecular Biology, Iladevi Cataract and IOL Research Centre, Ahmedabad, Gujarat, India.
Kaid JoharDepartment of Zoology, BMTC and Human Genetics, School of Sciences, Gujarat University, Ahmedabad, India.
Krishna B S SwamyBiological and Life Sciences, School of Arts and Sciences, Ahmedabad University, Ahmedabad, 380009, Gujarat, India.
Shanaya PatelBiological and Life Sciences, School of Arts and Sciences, Ahmedabad University, Ahmedabad, 380009, Gujarat, India. shanaya.patel@ahduni.edu.in.
Vivek TanavdeBiological and Life Sciences, School of Arts and Sciences, Ahmedabad University, Ahmedabad, 380009, Gujarat, India. vivek.tanavde@ahduni.edu.in.
Ahmedabad University · INHCG Cancer Centre · INAgency for Science, Technology and Research · SGGujarat University · IN

Funding

DBT-Wellcome Trust India Alliance IA/E/20/1/505666Wellcome Trust
6 · The paper itself

Abstract

backgroundLate diagnosis is one of the major confounders in oral squamous cell carcinoma (OSCC). Despite recent advances in molecular diagnostics, no disease-specific biomarkers are clinically available for early risk prediction of OSCC. Therefore, it is important to identify robust biomarkers that are detectable using non-invasive liquid biopsy techniques to facilitate the early diagnosis of oral cancer. This study identified potential salivary exosome-derived miRNA biomarkers and crucial miRNA-mRNA networks/underlying mechanisms responsible for OSCC progression.

methodsSmall RNASeq (n = 23) was performed in order to identify potential miRNA biomarkers in both tissue and salivary exosomes derived from OSCC patients. Further, integrated analysis of The Cancer Genome Atlas (TCGA) datasets (n = 114), qPCR validation on larger patient cohorts (n = 70) and statistical analysis with various clinicopathological parameters was conducted to assess the effectiveness of the identified miRNA signature. miRNA-mRNA networks and pathway analysis was conducted by integrating the transcriptome sequencing and TCGA data. The OECM-1 cell line was transfected with the identified miRNA signature in order to observe its effect on various functional mechanisms such as cell proliferation, cell cycle, apoptosis, invasive as well as migratory potential and the downstream signaling pathways regulated by these miRNA-mRNA networks.

resultsSmall RNASeq and TCGA data identified 12 differentially expressed miRNAs in OSCC patients compared to controls. On validating these findings in a larger cohort of patients, miR-140-5p, miR-143-5p, and miR-145-5p were found to be significantly downregulated. This 3-miRNA signature demonstrated higher efficacy in predicting disease progression and clinically correlated with poor prognosis (p < 0.05). Transcriptome, TCGA, and miRNA-mRNA network analysis identified HIF1a, CDH1, CD44, EGFR, and CCND1 as hub genes regulated by the miRNA signature. Further, transfection-mediated upregulation of the 3-miRNA signature significantly decreased cell proliferation, induced apoptosis, resulted in G2/M phase cell cycle arrest and reduced the invasive and migratory potential by reversing the EMT process in the OECM-1 cell line.

conclusionsThus, this study identifies a 3-miRNA signature that can be utilized as a potential biomarker for predicting disease progression of OSCC and uncovers the underlying mechanisms responsible for converting a normal epithelial cell into a malignant phenotype.

Indexed as

BiomarkersDisease progressionEpithelial-mesenchymal transitionExosomal miRNAsOral squamous cell carcinomaSalivary exosomes

Identifiers

PMID37316916
PMCPMC10268489
OpenAlexW4380628297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.